DECN to Launch Genchoice! Product in Select Intern
Post# of 11802
(Total Views: 369)
Posted On: 12/04/2018 9:23:53 AM
DECN to Launch Genchoice! Product in Select International Markets January 2, 2019 and to File gor CE Mark in the EU and Health Canada Approval in Early 2019
LOS ANGELES, CA / ACCESSWIRE / December 4, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine"
diabetes test strip, the internationally launched GenSure! ("Feather" diabetes test strip, and the GenChoice! ("Ladybug" which is now in the process of completing its 510K application for filing with the U.S. FDA, the market ready PetSure! test strip for the diabetic testing of dogs and cats, the market ready GenUltimate! 4Pets system (new) also for the diabetic testing of dogs and cats, and the panacea GenPrecis! ("Dragonfly" diabetes testing system, ready for clinical trials.
Keith Berman, CEO of Decision Diagnostics stated, ''The receipt of the completed report from the company's IRB is an important event for the company. It indicates that we have reached a milestone for our GenChoice! product where we now have proven technology that meets or exceeds all FDA and ISO (international) standards. We anticipate filing the 510K application with the FDA for their review on December 21, 2018.''
Mr. Berman continued, ''We view GenChoice! as the first necessary advance of our business model where our ''Gen'' brand will become the low priced but high quality alternative for a number of legacy glucose test strips. GenChoice is the second of four anticipated alternative test strips for the legacy systems that account for approximately 71% of the U.S. market, and at even higher levels in the EU. We plan to launch GenChoice! in select International markets on January 2, 2019. We will update our web sites with images of the GenChoice! international packaging in the next several weeks.''
Mr. Berman concluded, ''In the next 10 days, we also intend to discuss a major advance to our GenPrecis! test strip and meter, allowing us, hopefully, to shorten the time for U.S. FDA clearance which will evolve our panacea product to become a savior product for one of the legacy system companies. Please stay tuned for this upcoming announcement.''
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of December 3, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
LOS ANGELES, CA / ACCESSWIRE / December 4, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine"
diabetes test strip, the internationally launched GenSure! ("Feather" diabetes test strip, and the GenChoice! ("Ladybug" which is now in the process of completing its 510K application for filing with the U.S. FDA, the market ready PetSure! test strip for the diabetic testing of dogs and cats, the market ready GenUltimate! 4Pets system (new) also for the diabetic testing of dogs and cats, and the panacea GenPrecis! ("Dragonfly" diabetes testing system, ready for clinical trials. Keith Berman, CEO of Decision Diagnostics stated, ''The receipt of the completed report from the company's IRB is an important event for the company. It indicates that we have reached a milestone for our GenChoice! product where we now have proven technology that meets or exceeds all FDA and ISO (international) standards. We anticipate filing the 510K application with the FDA for their review on December 21, 2018.''
Mr. Berman continued, ''We view GenChoice! as the first necessary advance of our business model where our ''Gen'' brand will become the low priced but high quality alternative for a number of legacy glucose test strips. GenChoice is the second of four anticipated alternative test strips for the legacy systems that account for approximately 71% of the U.S. market, and at even higher levels in the EU. We plan to launch GenChoice! in select International markets on January 2, 2019. We will update our web sites with images of the GenChoice! international packaging in the next several weeks.''
Mr. Berman concluded, ''In the next 10 days, we also intend to discuss a major advance to our GenPrecis! test strip and meter, allowing us, hopefully, to shorten the time for U.S. FDA clearance which will evolve our panacea product to become a savior product for one of the legacy system companies. Please stay tuned for this upcoming announcement.''
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN's products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $12 billion at-home testing market.
Forward-Looking Statements:
This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of December 3, 2018, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
CONTACT INFORMATION:
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
(2)
(0)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼